Search Results for: stem cell biotech

New FDA IntelliCell BioSciences, Audit Report: A Lot of Work to Do

IntelliCell BioSciences, Inc. of New York, a clinical stem cell establishment, has had a rough time of it lately. For example, a recent piece of bad news is that there is an impending foreclosure sale of the company’s assets. What exactly that means for the company more broadly remains unknown, but a few people tell me (take this

New FDA IntelliCell BioSciences, Audit Report: A Lot of Work to Do Read More »

Stem Cells An Insider’s Guide: More on My New Book

In about a month my new book, Stem Cells: An Insider’s Guide, should be available as an e-book from the publisher and from Amazon. It’s available for pre-order now at Amazon here. The “real” book (i.e. the one made of paper) should be available in September. The book costs $29. Any writers out there interested in doing

Stem Cells An Insider’s Guide: More on My New Book Read More »

Celltex FDA FOIA letter #2: no safety concerns with our stem cells, which really are not drugs

A FOIA request that I made with the FDA in mid-December 2012 has at long last revealed  letters from Celltex  to the FDA that previously were not in the public domain. The reason for the FOIA and for these blog posts is to shed some light on important issues that particularly relate to patient safety. I

Celltex FDA FOIA letter #2: no safety concerns with our stem cells, which really are not drugs Read More »

Interview with BioTime CEO Michael West Part 1: a little stem cell history

Michael-West-PhD-CEO-of-BioTime-1-934x10241

It was my pleasure recently to  talk at length with Dr. Michael West, CEO of the Stem Cell Biotech, BioTime (BTX). West has been at the helm of BioTime since 2007 and is a true pioneer in the stem cell field. He founded Geron (GERN) and was a top leader at Advanced Cell Technology (ACT; stock

Interview with BioTime CEO Michael West Part 1: a little stem cell history Read More »

My response to ‘Our Bodies, Our Cells’ Harvard post on deregulation

Mary-Ann-Chirba

Over at the Harvard Law “Bill of Health” blog, Mary Ann Chirba and Alice A. Nobel posted a piece entitled “Our Bodies, Our Cells” a few days ago that has generated a lot of discussion about FDA regulation of stem cell interventions. Their piece really has two parts. In the first part they go through

My response to ‘Our Bodies, Our Cells’ Harvard post on deregulation Read More »

Stem cell company Intellicell facing new financial wrinkles

Intellicell

It’s difficult to make it as a biotech company, I would say stem cell biotechs in general may have an even rougher time, and one such company,  Intellicell (Intellicell Biosciences, Inc), is showing a number of signs of distress in my opinion. An online financial tool predicts the probability of companies going bankrupt within the next

Stem cell company Intellicell facing new financial wrinkles Read More »